Diabetology & Metabolic Syndrome最新文献

{"title":"Correction: Low carbohydrate diets, glycaemic control, enablers, and barriers in the management of type 1 diabetes: a mixed methods systematic review.","authors":"Janine Paul, Rati Jani, Sarah Thorning, Mila Obucina, Peter Davoren, Catherine Knight-Agarwal","doi":"10.1186/s13098-025-01654-3","DOIUrl":"10.1186/s13098-025-01654-3","url":null,"abstract":"","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"92"},"PeriodicalIF":3.4,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11924757/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143662988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Body mass index modifies the major adverse cardiovascular and cerebral events risk of NT-proBNP in patients with acute coronary syndrome.","authors":"Xiaoquan He, Xiaojing Fang, Jiali Wang, Shumei Zhao, Xiaosong Ding, Hui Chen","doi":"10.1186/s13098-025-01668-x","DOIUrl":"10.1186/s13098-025-01668-x","url":null,"abstract":"<p><strong>Background: </strong>Little is known about the relationship between body mass index (BMI) and the prognostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with acute coronary syndrome (ACS). This study aimed to investigate how BMI modifies the association between NT-proBNP levels and clinical outcomes in ACS patients.</p><p><strong>Methods: </strong>A total of 11,757 ACS patients from the Cardiovascular Centre Beijing Friendship Hospital were recruited. The association between NT-proBNP and major adverse cardiovascular and cerebral events (MACCEs) was assessed using multivariate Cox proportional hazards models. The multiplicative interaction between NT-proBNP and BMI was evaluated using the Wald χ² test.</p><p><strong>Results: </strong>During the median follow-up time of 3.04 (IQR: 1.07‒5.02) years (33,232 person-years), 1996 MACCEs were documented. A significant multiplicative interaction was observed between natural logarithm (Ln)-NT-proBNP and BMI (p for multiplicative interaction = 0.013). The categorical thresholds of NT-porBNP for the risk of MACCEs were 1559, 155, and 419 pg/ml for normoweight, overweight, and obese patients, respectively. When NT-proBNP levels were near-normal or mildly elevated (≤ 300 pg/ml), overweight and obese patients exhibited a higher event probability than normoweight patients at a given NT-proBNP level. However, an opposite trend was observed at significantly elevated NT-proBNP levels (> 300 pg/ml), with normoweight patients showing a higher event probability. When BMI and NT-proBNP were considered jointly, normoweight patients with elevated NT-proBNP had a significantly higher risk of MACCEs than overweight patients without elevated NT-proBNP (hazard ratio: 2.28; 95% confidence interval: 1.83‒2.84; p < 0.001).</p><p><strong>Conclusion: </strong>The prognostic value of NT-proBNP in ACS patients varies with BMI, with the extent of NT-proBNP elevation playing a role in this relationship.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"88"},"PeriodicalIF":3.4,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11916518/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between the haemoglobin glycation index and 30-day and 365-day mortality in patients with heart failure admitted to the intensive care unit.","authors":"Ziyu Guo, Yike Li, Shuoyan An, Jingang Zheng","doi":"10.1186/s13098-025-01661-4","DOIUrl":"10.1186/s13098-025-01661-4","url":null,"abstract":"<p><strong>Background: </strong>The hemoglobin glycation index (HGI) represents the difference between the observed and predicted values of haemoglobin A1c (HbA1c). However, the association between HGI and prognosis of heart failure (HF) is not completely clarified yet and requires more investigation. This study aimed to explore the connection between HGI and mortality in HF patients.</p><p><strong>Methods: </strong>The data for the study were derived from the MIMIC-IV database from 2008 to 2019, a publicly available clinical database in intensive care. A linear regression equation between HbA1c and fasting blood glucose (FBG) was established to calculate predicted HbA1c. The endpoints were 30-day and 365-day all-cause mortality. Kaplan-Meier analysis was utilized to compare survival rates across groups differentiated by their HGI levels. The Cox regression models and restricted cubic spline (RCS) analysis were utilized to analyze the association between HGI and mortality.</p><p><strong>Results: </strong>The study collected a total of 2846 patients with HF (40.1% male), of whom 305 patients (10.7%) died within 30 days and 954 patients (33.5%) died within 365 days. Kaplan-Meier curves revealed patients with higher HGI had significantly higher mortality risks (log-rank P < 0.001). A high HGI was significantly associated with 30-day mortality (adjusted HR [aHR]: 2.36, 95% CI: 1.74-3.20, P < 0.001) and 365-day mortality (aHR: 1.40, 95% CI: 1.16-1.68, P < 0.001) after adjustment for potential confounders. Likewise, each unit increase in the HGI correlated with a 1.42-fold higher risk of 30-day mortality (aHR: 1.42, 95% CI: 1.28-1.57, P < 0.001) and 1.19-fold higher risk of 365-day mortality (aHR: 1.19, 95% CI: 1.11-1.68, P < 0.001). RCS analysis suggested an L-shaped nonlinear association between HGI and clinical endpoints (P for nonlinearity < 0.001), with an inflection point value of - 1.295. Subgroup analysis and sensitivity analysis revealed that the correlation between HGI and 30-day and 365-day all-cause mortality remained consistent.</p><p><strong>Conclusions: </strong>In ICU-admitted HF patients, HGI was independently associated with increased risks of 30-day and 365-day mortality and the identification of high HGI (> 0.709) provided a valuable tool for clinicians to detect high-risk populations. Integrating HGI into routine clinical practice might strengthen the prognosis-based decision making improve HF patient outcomes.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"87"},"PeriodicalIF":3.4,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11916851/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the interplay between adipokine-mediated celastrol target genes and T cells in diabetic nephropathy: a mendelian randomization-based causal inference.","authors":"Xiaojuan Wang, Mohamad Hafizi Abu Bakar, Mohd Asyraf Kassim, Khairul Anuar Shariff, Jing Wang, Manli Xu","doi":"10.1186/s13098-025-01665-0","DOIUrl":"10.1186/s13098-025-01665-0","url":null,"abstract":"<p><strong>Background: </strong>Diabetic nephropathy (DN) is influenced by dysregulated adipokines, which play a key role in inflammation, immune responses, and lipid metabolism. However, the precise molecular mechanisms linking adipokine dysregulation, immune cell infiltration, and metabolic reprogramming in DN remain poorly understood. Celastrol, a bioactive lipid regulator, has been shown to mitigate renal immune-inflammatory damage by inhibiting the PI3K/Akt/NF-κB signaling pathway. Yet, its specific impact on adipokine-mediated immune responses and lipid metabolism in DN is unclear. This study aims to elucidate the interplay between adipokine-mediated target genes in DN and investigate how celastrol modulates these interactions.</p><p><strong>Methods: </strong>Gene expression profiles of DN patients were obtained from GEO datasets (GSE30122 and GSE30528) and analyzed for differentially expressed genes (DEGs) using the limma package. Gene set variation analysis (GSVA) was conducted to assess lipid metabolism pathways, while Mendelian randomization (MR) and Pearson correlation evaluated the association between DEGs and adipokines. Immune cell infiltration was analyzed using the IOBR R package (MCP-counter and xCell methods), followed by MR analysis of DN-related immune responses. Celastrol target genes were identified using the SEA database.</p><p><strong>Results: </strong>A total of 70 intersecting DEGs were identified. GSVA revealed that brown and beige adipocyte differentiation pathways were downregulated, while adipocyte-related pathways were upregulated in DN (p < 0.05). MR analysis demonstrated that adiponectin was negatively associated with DN (OR = 0.77, P = 0.005), whereas leptin (OR = 1.92, P = 0.016) and resistin (OR = 1.43, P < 0.001) were positively associated. Three key genes, MAGI2, FGF9, and THBS2 were linked to DN risk and T cell infiltration. THBS2 was positively correlated with T cell infiltration (OR = 0.51, P = 6.7e-06), while FGF9 (OR = -0.8, P = 2.2e-16) and MAGI2 (OR = 0.75, P = 1.3e-13) were negatively correlated. 22 celastrol target genes, including MAGI2, FGF9, and THBS2, were identified.</p><p><strong>Conclusion: </strong>Our findings reveal that celastrol modulates DN progression through adipokine-immune crosstalk, with FGF9, MAGI2, and THBS2 emerging as key regulatory genes. These insights provide new avenues for biomarker discovery and therapeutic implications in the development of DN.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"89"},"PeriodicalIF":3.4,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921554/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic impact of prediabetes on long-term cardiovascular outcomes in patients under 35 with premature acute myocardial infarction.","authors":"Xinlong Zhao, Yuansong Zhuang, Siqi Tang, Yanping Ruan, Quan Li, Yanbo Liu, Jinyan Lei, Yitao Han, Yuxiong Chen, Yakun Zhao, Zhongjie Fan","doi":"10.1186/s13098-025-01662-3","DOIUrl":"10.1186/s13098-025-01662-3","url":null,"abstract":"<p><strong>Background: </strong>Prediabetes (pre-DM) is recognized as an intermediate state of glucose metabolism with a high potential to progress to diabetes mellitus (DM). However, its prognostic value in patients with premature acute myocardial infarction (PAMI) under the age of 35 remains unclear. This study aimed to investigate the relationship between pre-DM and long-term cardiovascular outcomes in this unique population.</p><p><strong>Methods: </strong>This retrospective cohort study included 796 PAMI patients under 35 years of age who were categorized into three groups based to glycated hemoglobin levels or previous history: normal glucose regulation (NGR), pre-DM, and DM. The primary endpoint was the occurrence of major adverse cardiovascular and cerebrovascular events (MACCE) including all-cause death, non-fatal myocardial infarction, non-fatal stroke, or revascularization. Multivariable Cox regression, Kaplan-Meier and Subgroup analyses were performed.</p><p><strong>Results: </strong>Pre-DM was observed in 22.1% of the PAMI cohort. During the median follow-up of 81 months, the incidence of MACCE was 23.5%, with significantly higher rates in the pre-DM and DM group compared to the NGR group (18.4%, 27.3%, 34.2%; p < 0.001). After adjusting for confounding variables, pre-DM remained independently associated with an increased risk of MACCE (HR 1.51, 95%CI 1.05-2.18, p = 0.027). Subgroup analysis demonstrated that pre-DM status was a robust risk factor compared to NGR. Moreover, pre-DM had a similar impact on MACCE events as DM in patients with PAMI.</p><p><strong>Conclusions: </strong>Pre-DM is associated with a poor prognosis in young AMI patients under 35 years old, suggesting that it may be an independent predictor of adverse events in this population.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"90"},"PeriodicalIF":3.4,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921701/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disturbances in the gut microbiota potentially associated with metabolic syndrome among patients living with HIV-1 and on antiretroviral therapy at Bafoussam Regional Hospital, Cameroon.","authors":"Joël Martial Diesse, Sushama Jadhav, Stephen Lacmata Tamekou, Gustave Simo, Jean Paul Dzoyem, Jacob Souopgui, Jules-Roger Kuiate, Vijay Nema","doi":"10.1186/s13098-025-01653-4","DOIUrl":"10.1186/s13098-025-01653-4","url":null,"abstract":"<p><strong>Background: </strong>This study investigates the gut microbiota components associated with metabolic syndrome in patients living with HIV-1 at Bafoussam Regional Hospital, West Cameroon, it focuses on gastrointestinal mucosal barrier disruption and dysbiosis, and their effects on persistent inflammation and metabolic disorders.</p><p><strong>Methods: </strong>A pilot study was conducted involving fourteen patients living with HIV-1. The patients were divided into two groups of seven in each group. One group consisted of patients with metabolic syndrome, and the other group included patients without metabolic syndrome. Gut microbiota was characterized using 16 S rRNA gene-targeted sequencing to analyze microbial diversity and composition. Beta diversity and the relative abundance of bacterial taxa were compared between patients with and without metabolic syndrome.</p><p><strong>Results: </strong>Patients living with HIV-1 and metabolic syndrome showed significantly altered beta diversity compared to those without metabolic syndrome. A higher relative abundance of Firmicutes and increased proliferation of Proteobacteria were observed in patients with metabolic syndrome. Additionally, a decrease in metabolically beneficial bacteria, such as Bifidobacterium sp., Lactobacillus sp., Akkermansia sp., and Faecalibacterium sp., was noted. Several beneficial bacterial species were associated with participants' metadata, suggesting potential links between gut microbiota and metabolic syndrome.</p><p><strong>Conclusion: </strong>This preliminary study highlights that gut microbial balance, rather than the presence of specific bacteria, plays a crucial role in managing metabolic health in patients living with HIV-1. The altered gut microbiota in participants with metabolic syndrome emphasizes the need for further research into the optimal gut microbial structure. Understanding the interaction between gut microbiota changes and the chemical environment in these patients could guide targeted interventions to improve metabolic outcomes.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"86"},"PeriodicalIF":3.4,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909933/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143633711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"U-shaped relationship of estimated glucose disposal rate with cardiovascular disease risk in cardiovascular-kidney-metabolic syndrome stages 0-3: a population-based prospective study.","authors":"Xiaomin Liang, Kai Lai, Xiaohong Li, Shuiqing Gui, Zemao Xing, Ying Li","doi":"10.1186/s13098-025-01659-y","DOIUrl":"10.1186/s13098-025-01659-y","url":null,"abstract":"<p><strong>Background: </strong>Cardiovascular-Kidney-Metabolic (CKM) syndrome is characterized by the interrelatedness of chronic kidney disease (CKD), cardiovascular disease (CVD), and metabolic disorders. The relationship between estimated glucose disposal rate (eGDR) and CVD risk in CKM syndrome remains unclear.</p><p><strong>Methods: </strong>We analyzed data from 7,849 participants aged ≥ 45 years in the China Health and Retirement Longitudinal Study (CHARLS). The eGDR was calculated using waist circumference, hypertension, and HbA1c. Cox regression and restricted cubic spline (RCS) regression analyses examined the association between eGDR and CVD (stroke or cardiac events).</p><p><strong>Results: </strong>During a mean follow-up of 8.29 ± 1.67 years, among 7,849 participants (mean age 62.4 ± 8.7 years; 52.82% male), 1,946 CVD events occurred, including 1,504 cardiac events and 663 strokes. CKM stages 0-3 comprised 492 (6.27%), 1,404 (17.89%), 5,462 (69.59%), and 491 (6.26%) of participants, respectively. A U-shaped relationship between eGDR and CVD risk was identified (turning point: 11.82 mg/kg/min). Below this turning point, each unit increase in eGDR decreased CVD risk by 12% (HR: 0.88, 95% CI: 0.86-0.90, P < 0.0001); above it, each unit increase raised the risk by 19% (HR: 1.19, 95% CI: 1.04-1.37, P = 0.0135).</p><p><strong>Conclusion: </strong>Our findings reveal a U-shaped relationship between eGDR and CVD risk in CKM syndrome stages 0-3. A higher or lower eGDR was associated with an increased CVD risk.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"85"},"PeriodicalIF":3.4,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11895221/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143603077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent advances in understanding the mechanisms by which sodium-glucose co-transporter type 2 inhibitors protect podocytes in diabetic nephropathy.","authors":"Xinqi Chen, Mingjie Wang, Zhaoli Yan","doi":"10.1186/s13098-025-01655-2","DOIUrl":"10.1186/s13098-025-01655-2","url":null,"abstract":"<p><strong>Background: </strong>Diabetes mellitus is associated with systemic damage across multiple organ systems, and an increasing number of patients are presenting with diabetic kidney disease as its initial manifestation. The onset and progression of diabetic nephropathy is closely associated with podocyte injury.</p><p><strong>Main body: </strong>Sodium-glucose cotransporter type 2 (SGLT2) inhibitors, which can significantly reduce glucose levels as well as protecting against kidney damage, are therefore widely used for the clinical treatment of patients with diabetic kidney disease. An increasing body of research has revealed that the renal protective effect of SGLT2 inhibitors is primarily derived from their enhancement of podocyte autophagy and their inhibition of inflammation and podocyte apoptosis. Multiple signaling pathways are involved in these processes.</p><p><strong>Conclusion: </strong>A deeper exploration of the renal protective effects of SGLT2 inhibitors and the underlying mechanisms will provide more solid theoretical support for their application in the prevention and treatment of diabetic kidney disease.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"84"},"PeriodicalIF":3.4,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11887226/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143571611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between metabolic visceral fat score and left ventricular hypertrophy in individuals with type 2 diabetes.","authors":"Lu Wang, Simo Liu, Jing Ke, Bin Cao, Di Wang, Qianqian Zhao, Haolin Gong, Yuan Fang, Zhaohui Zheng, Caiguo Yu, Nannan Wu, Yan Ma, Ke Yu, Longyan Yang, Dong Zhao","doi":"10.1186/s13098-025-01648-1","DOIUrl":"10.1186/s13098-025-01648-1","url":null,"abstract":"<p><strong>Background: </strong>Left ventricular hypertrophy (LVH), a hallmark of early-stage heart failure (HF), is a common complication in individuals with type 2 diabetes mellitus (T2DM). Metabolic Visceral Fat Score (METS-VF), a novel metric for estimating visceral adiposity, may provide valuable insights into LVH risk. This study explores the association between METS-VF and LVH in T2DM and compare its predictive performance to traditional abdominal obesity indices.</p><p><strong>Methods: </strong>This cross-sectional study included 4,988 adults with T2DM. Participants were stratified into quartiles based on METS-VF. Logistic regression models assessed the association between METS-VF and LVH. Restricted cubic spline analyses evaluated nonlinear relationships, while stratified analyses explored subgroups effects. Receiver operating characteristic (ROC) curves compared the predictive performance of METS-VF with other indices.</p><p><strong>Results: </strong>LVH prevalence increased across METS-VF quartiles (Quartile 1: 7.9%; Quartile 2: 13.0%; Quartile 3: 20.0%; Quartile 4: 31.0%; P < 0.001). Higher METS-VF was independently associated with LVH (OR: 9.79; 95% CI: 6.16-15.76; P < 0.001). A nonlinear relationship was observed between METS-VF and LVH, with a steeper risk increase above specific thresholds. Stratified analyses showed that the positive association between METS-VF and LVH was consistent. METS-VF outperformed traditional indices in predicting LVH (AUC: 0.68; 95% CI: 0.66-0.70).</p><p><strong>Conclusions: </strong>METS-VF is strongly associated with LVH in T2DM, demonstrating superior predictive performance compared to traditional indices. METS-VF is a practical, cost-effective tool for early cardiac risk stratification, facilitating timely interventions to mitigate HF risk in T2DM populations.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"81"},"PeriodicalIF":3.4,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884144/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143572492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of obesity and LDL subfractions evaluated by body mass index, waist circumference, and diabetes status: the ELSA-Brasil study.","authors":"Eugenio G Moraes, Giuliano Generoso, Isabela M Bensenor, Raul D Santos, Itamar S Santos, Alessandra C Goulart, Steven R Jones, Krishnaji R Kulkarni, Michael J Blaha, Peter P Toth, Paulo A Lotufo, Marcio Sommer Bittencourt","doi":"10.1186/s13098-025-01644-5","DOIUrl":"10.1186/s13098-025-01644-5","url":null,"abstract":"<p><p>Low-density lipoproteins (LDL) comprise a pool of particles with different densities that may have variable impact on atherogenesis. Studies suggest that obese individuals with elevated body mass index (BMI) and waist circumference (WC) have increased small and dense LDL subfractions (sdLDL-c). It is unclear if diabetes (T2D) and insulin resistance (IR) may modify this association. We included 4,111 (50.4 ± 8.6 years of age, 45.5% men) individuals with neither prior cardiovascular disease nor use of lipid-lowering medications. Total LDL-c and its subfractions (LDL₁-c, LDL₂-c, LDL₃-c, and LDL₄-c) were measured by vertical zonal ultracentrifugation. We considered the subfractions LDL₁-c and LDL₂-c as large buoyant LDL (lbLDL-c) and the subfractions LDL₃-c and LDL₄-c as sdLDL-c. We analyzed the association between LDL-c subclasses, BMI and WC using linear regression analysis and stratified by the presence of T2D and IR. For sdLDL-c, a direct association with hypertension, T2D, fasting plasma glucose, total cholesterol, LDL-c, and triglycerides was observed. In multivariate analysis, after adjustment for age, sex, race and triglycerides, the strong association of sdLDL-c with BMI (β 95% CI 0.16 (0,13-0,19)) and WC (β 95% CI 0.22 (0.19-0.26)) persisted. After stratification, the association of sdLDL-c and WC was present only in those with insulin resistance or diabetes. BMI showed a smaller impact than WC on this association. WC and BMI were strongly associated with sdLDL-c subfractions. Further, this association was modified by diabetes and insulin resistance status.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"83"},"PeriodicalIF":3.4,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11887076/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143572499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}